Parkinson Disease
Conditions
Interventions
Experimental group: thirty people from 40 years of age, of both sexes, diagnosed with Parkinson's Disease and in physical conditions to participate in the activities proposed in the intervention, as e
Sponsors
Universidade Federal do Pará
Universidade Federal do Pará
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis according to the UK Parkinson's Disease Society Brain Bank; Hoehn and Yahr stage I to III; under pharmacological treatment for at least 3 years; and in physical conditions to perform the dance intervention.
Exclusion criteria
Exclusion criteria: People without physical conditions to perform the tests and dance intervention; who have other neurological or neuropsychiatric conditions; or have serious comorbidities that may pose a risk for the practice of physical activities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1. Improvement of motor and balance functions, assessed by the Timed Up-and-Go Test (TUG) (Greene et al. 2010), Performance Oriented Balance Assessment (POMA) (Faber et al. 2006) and the Berg Balance Scale (BBS) (Kornetti et al. 2004) associated with the use of accelerometry protocols. The improvements are expected to be inside the clinically meaningful results observed for aged people which range in between 6 and 10% of motor improvements in several scales. These results may not represent statistically significant differences, but on the clinical scenario they improve meaningfully the quality of life and performance on daily activities of patients, especially regarding a incurable and progressive degenerative disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2. Improvement of cognitive functions, assessed by the "Frontal Assessment Battery - FAB" (Dubois et al. 2000) and the "mental rotation test" (Mental Rotation Task - MRT) (Hegarty 2018). For these tests, significant improvements on the whole score calculated by t test between scores before and after intervention, on the whole test or in any of its subdivisions, considering a confidence interval of 95% will be considered relevant.;Expected outcome 3. Improvement of neuropsychiatric effects as assessed by the apathy scale (AS) (Marin et al. 1991) and the Montgomery and Asberg depression scale (MADRS) (Snaith et al. 1986). For apathy Scale the results range between 0 and 42, with a score of 14 considered indicative of clinically meaningful apathy, therefore reductions beyond this range will differentiate between the presence of the condition and its absence, For MADRS scale we will consider the reduction among 10% to be relevant.;Expected outcome 3. Improvement of biochemical changes associated with Parkinson Disease through blood collection, especially the interleucins related to the infammatory responses (e.g. IL-4 and 6) which is well described to be involved in neural cell death mechanisms in several neuropathologic conditions. We expect that the interleucins levels will be altered in al patients, and the outcome of the intervention according to our hypothesis should bring them closer to the normal ranges described in the literature. Changes around 5% of the difference between the normal and the observed initial range will be considered as relevant. | — |
Countries
Brazil
Contacts
Public ContactJuliana Duarte
Universidade Federal do Pará
Outcome results
None listed